The Cancer Letter

Inside information on cancer research and drug development

In Brief

LifeCare Alliance, Ohio State collaborate to advance cancer health equity

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

LifeCare Alliance and the Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Center and Richard J. Solove Research Institute announced a  partnership aimed at enhancing access to breast cancer screening and diagnostics for underserved individuals across Ohio.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Guest Editorial

Moving from mandate to mission: Community outreach and engagement at NCI-designated cancer centers
“COE is broken.”

Acting Director Dr. Krzysztof Ptak’s words reverberated throughout the meeting room—and the heads of several of us—during the National Cancer Institute’s Office of Cancer Centers update on the final day of the 2024 Association of American Cancer Institutes/Cancer Center Administrators Forum Annual Meeting in Chicago.
By Monica L. Baskin, Nadine J. Barrett, Kim F. Rhoads, Hayley S. Thompson, Kimlin Tam Ashing, Folakemi T. Odedina and Vanessa B. Sheppard
In Brief

VCU awarded $9M from NCI to establish Cancer Control Equity Research Center

Virginia Commonwealth University has been awarded a five-year, $9 million grant from NCI to establish a pioneering Cancer Control Equity Research Center. This initiative aims to enhance the dissemination and implementation of health promotion and cancer prevention services for individuals and families residing in Virginia’s Housing and Urban Development-administered income-based housing communities in the Greater Richmond region and Hampton Roads.
Clinical Roundup

MammaPrint test demonstrates utility in predicting chemotherapy benefit over five years

Agendia Inc. announced it will be presenting new data from the Real-World Data Registry, FLEX, demonstrating MammaPrint’s ability to predict chemotherapy benefit in patients with HR+HER2- early-stage breast cancer. The findings will be presented at the San Antonio Breast Cancer Symposium 2024. The MammaPrint test analyzes the 70 most important genes associated with breast cancer recurrence.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account